Labcorp to buy intellectual property from Myriad Genetics

By LabPulse.com staff writers

May 3, 2021 -- Labcorp plans to buy some of Myriad Genetics' operating assets and intellectual property from its autoimmune business unit, including its Vectra rheumatoid arthritis assay.

Vectra is a blood-based test that evaluates 12 biomarkers for rheumatoid arthritis activity. More than 1 million Vectra tests have been performed since Myriad launched it in 2010, according to Labcorp.

The deal is expected to close by the end of the third quarter of this year, the company said.

Labcorp adds new COVID-19 antigen test to repertoire
Labcorp has added a new high sensitivity antigen test for screening for active COVID-19 disease to its testing offerings. The nasal swab test was developed...
CDC awards Labcorp SARS-CoV-2 sequencing contract
The U.S. Centers for Disease Control and Prevention (CDC) has awarded Labcorp a contract to provide genomic sequencing of samples of the SARS-CoV-2 virus.
Labcorp gets EUA for Pixel at-home COVID-19 kits
Labcorp has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration for Pixel by Labcorp, a kit that will enable users...
Labcorp revenue, earnings surge in Q3
Revenue gains from COVID-19 testing helped propel Labcorp to a 33% increase in revenue in its third quarter. The company said that revenue climbed due...
Labcorp nabs EUA for new COVID-19 molecular test
The U.S. Food and Drug Administration has awarded Labcorp emergency use authorization (EUA) for a new, high-throughput method that uses heat and technology...

Copyright © 2021 LabPulse.com

Last Updated ls 5/3/2021 2:12:45 PM